Colospan

About

Funding history · 2 rounds · $17.0M total

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Colospan's primary focus?

Colospan is a clinical-stage medical device company developing proprietary technology for colorectal surgery to prevent anastomotic leaks and divert colonic stomas.

When was Colospan founded?

Colospan was founded in December 2010.

What is Colospan's lead product?

Colospan's lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site.

When did Colospan receive FDA approval for its intraluminal bypass device?

In January 2020, Colospan announced FDA approval of an IDE for its intraluminal bypass device.

Which hospital was the first in the U.S. to test Colospan's CG-100 device?

In December 2020, Henry Ford Hospital was the first in the U.S. to test Colospan's novel CG-100 intraluminal device in patients undergoing colorectal anastomosis.

When did Colospan accelerate its FDA pivotal trial and appoint a new board member?

In October 2021, Colospan accelerated its FDA pivotal trial and appointed Gregory D. Casciaro to its Board of Directors.

How much funding did Colospan receive from the European Innovation Council?

In December 2021, Colospan received €8.2 million from the European Innovation Council for its colorectal surgery device.

What was the amount of Colospan's first disclosed funding round and who were some of the investors?

In September 2017, Colospan raised $7.7 million in an undisclosed round with investors including Anatomy Medical Technology Fund and Docor International Management. For full financing history, refer to startupim.

How many employees does Colospan currently have?

Colospan currently has 11 employees.

Sectors & technology

Highlights

Tags